The CARDIOPROTECT Trial
A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial
Beth Israel Deaconess Medical Center
60 participants
Aug 31, 2026
INTERVENTIONAL
Conditions
Summary
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments. The names of the study drugs involved in this study are: * Dexrazoxane (a type of Topoisomerase II Inhibitor) * Liposomal Doxorubicin (a type of Topoisomerase II Inhibitor) * Standard of care R-CHOP treatment regimen (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) * Standard of care pola-R-CHP treatment regimen: Cyclophosphamide, doxorubicin, polatuzumab vedotin-piiq, prednisone, rituximab
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Topoisomerase II Inhibitor, single-dose vial, via intravenous infusion per protocol.
Dexrazoxane placebo via intravenous infusion per protocol.
Topoisomerase II Inhibitors, single-dose vial, via intravenous infusion per protocol.
Topoisomerase II Inhibitors, single-dose vial, via intravenous infusion per protocol.
Lymphodepleting chemotherapy, multi-dose vial, via intravenous infusion per standard of care.
vinca alkaloid, single-dose vial, via intravenous infusion per standard of care.
Glucocorticoid, tablet taken orally per standard of care.
Anti-CD20 antibody, single-use vials, via intravenous infusion per standard of care.
CD79b-directed antibody-drug conjugate, single-dose vial, via intravenous infusion per standard of care.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07654426